These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19000174)

  • 21. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
    Dallow NS; Leonov SL; Roger JH
    Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data safety and monitoring boards for African clinical trials.
    Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing quality of reports on randomized clinical trials in nursing journals.
    Parent N; Hanley JA
    Can J Cardiovasc Nurs; 2009; 19(2):25-39. PubMed ID: 19517902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpreting age-related aspects of antihypertensive treatment: statistical defects and their remedy.
    Murray GD; Lesaffre E; Robertson JI
    J Hypertens Suppl; 1988 Nov; 6(1):S121-6. PubMed ID: 3063787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the validity of clinical trials.
    Akobeng AK
    J Pediatr Gastroenterol Nutr; 2008 Sep; 47(3):277-82. PubMed ID: 18728521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Methodological deficiencies in clinical trials].
    Nahler G
    Fortschr Med; 1992 Oct; 110(28):511-4. PubMed ID: 1398408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of RCT evidence depends on the quality of statistical analysis.
    Faulkner C; Fidler F; Cumming G
    Behav Res Ther; 2008 Feb; 46(2):270-81. PubMed ID: 18191102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of missing data in palliative care studies.
    Palmer JL
    J Pain Symptom Manage; 2004 Dec; 28(6):612-8. PubMed ID: 15589087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical researchers and the pharmaceutical industry. Usefulness and need for an independent steering committee].
    Van Gijn J; Algra A
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1477-9. PubMed ID: 10443264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Information-based monitoring of clinical trials.
    Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3236-44; discussion 3320-5, 3326-47. PubMed ID: 16927248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling overdispersion in longitudinal count data in clinical trials with application to epileptic data.
    Fotouhi AR
    Contemp Clin Trials; 2008 Jul; 29(4):547-54. PubMed ID: 18308644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Playing safe and preserving integrity: making the FDA model work.
    Wittes J
    Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality assurance in clinical trials.
    Feigenbaum SL
    Semin Reprod Endocrinol; 1996 May; 14(2):93-100. PubMed ID: 8796931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.